# Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL

> **NCT01686165** · PHASE2 · COMPLETED · sponsor: **University of Arizona** · enrollment: 5 (actual)

## Conditions studied

- Anaplastic Large Cell Lymphoma
- Recurrent Adult Diffuse Large Cell Lymphoma
- Recurrent Mantle Cell Lymphoma

## Interventions

- **DRUG:** belinostat
- **BIOLOGICAL:** rituximab
- **RADIATION:** yttrium Y 90 ibritumomab tiuxetan

## Key facts

- **NCT ID:** NCT01686165
- **Lead sponsor:** University of Arizona
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08-31
- **Primary completion:** 2016-02-09
- **Final completion:** 2017-11-09
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2018-08-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01686165

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01686165, "Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01686165. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*